Rapid urine antigen testing for Streptococcus pneumoniae in adults with community-acquired pneumonia: clinical use and barriers.
Diagn Microbiol Infect Dis. 2014 Aug;79(4):454-7.
Harris AM1, Beekmann SE2, Polgreen PM2, Moore MR3.
1Respiratory Disease Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: firstname.lastname@example.org
2University of Iowa Carver College of Medicine, Iowa City, Iowa.
3Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
Streptococcus pneumoniae (pneumococcus) is the most common bacterial etiology of community-acquired pneumonia (CAP) in adults, a leading cause of death.
The majority of pneumococcal CAP is diagnosed by blood culture, which likely underestimates the burden of disease.
The 2007 CAP guidelines recommend routine use of the rapid pneumococcal urinary antigen (UAg) test.
To assess the how pneumococcal UAg testing is being used among hospitalized adult CAP patients and what barriers restrict its use, a Web-based survey was distributed in 2013 to 1287 infectious disease physician members of the Emerging Infectious disease Network of the Infectious Disease Society of America. Of 493 eligible responses, 65% use the pneumococcal UAg test.
The primary barrier to UAg use was availability (46%). UAg users reported ordering fewer other diagnostic tests and tailoring antibiotic therapy. Increased access to UAg tests could improve pneumonia management and pneumococcal CAP surveillance.